Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
TEVA · NYSE · United States · Pharmaceutical Preparations
In shortTEVA PHARMACEUTICAL INDUSTRIES LTD is profitable, generates cash and holds more cash than debt, with revenue growing (+4.3% last year).
Financial health
Solid
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | 12.5% | 58/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | 8.2% | 53/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | 21.2% | 100/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | 17.5% | 100/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 1.04× | 20/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 0.23× | 98/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | Net cash | 100/100 |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | 2.35× | 8/100 |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -0.41 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 6.7% | 47/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | 0.81× | 64/100 |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 2 of 5 | 40/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 5.7% | 90/100 |
| Operating margin volatility | 11.0% | 9/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | 5.0% | 44/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 15,878 | 14,925 | 15,846 | 16,544 | 17,258 |
| Cost of revenue | 8,284 | 7,952 | 8,200 | 8,481 | 8,320 |
| Gross profit | 7,594 | 6,973 | 7,645 | 8,064 | 8,938 |
| Research & development | 967 | 98 | 953 | 998 | 1,013 |
| Operating income | 1,716 | (2,197) | 433 | (303) | 2,157 |
| Interest expense | 891 | 930 | 1,029 | 1,002 | 916 |
| Pre-tax income | 658 | (3,163) | (624) | (1,284) | 1,223 |
| Income tax | 211 | (643) | (7) | 676 | (180) |
| Net income | 417 | (2,446) | (559) | (1,639) | 1,410 |
| Diluted EPS | $0.38 | −$2.20 | −$0.50 | −$1.45 | $1.21 |
| Diluted shares (millions) | 1,107 | 1,110 | 1,119 | 1,131 | 1,163 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
−0.41 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
8/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 30, 2026 · Data updated Jul 29, 2026